

change in the temperature and pH limitations for sulphopropyl cellulose ion-exchange resin for the recovery and purification of proteins for food use.

Subsequent to the publication of the filing notice, it was determined that the proposed amendment of the provisions in § 173.25(b)(5) also necessitated an amendment of the provisions in § 173.25(d)(2), the paragraph that provides extraction requirements for the ion-exchange resin. Accordingly, the petitioner amended the petition to request an amendment of § 173.25(d)(2).

Therefore, FDA is amending the filing notice of July 22, 1996, to indicate that the petitioner requests that the food additive regulations be amended to modify the extraction requirements for sulphopropyl cellulose resin in § 173.25(d)(2).

The agency has determined under 21 CFR 25.32(i) that this action is of a type that does not individually or cumulatively have a significant effect on the human environment. Therefore, neither an environmental assessment nor an environmental impact statement is required.

Dated: August 3, 1998.

George H. Pauli,

Acting Director, Office of Premarket Approval, Center for Food Safety and Applied Nutrition.

[FR Doc. 98-23104 Filed 8-27-98; 8:45 am]

BILLING CODE 4160-01-F

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

Advisory Committee Meeting; Amendment of Notice

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice.

SUMMARY: The Food and Drug Administration (FDA) is announcing an amendment to the notice of a joint meeting of the Hematology and Pathology Devices Panel and the Immunology Devices Panel of the Medical Devices Advisory Committee that is scheduled for September 4, 1998. This meeting was announced in the **Federal Register** of August 13, 1998 (63 FR 43401). The amendment is being made to reflect changes in the *Date and Time* and *Procedure* portions of the meeting. There are no other changes.

FOR FURTHER INFORMATION CONTACT: Veronica J. Calvin, Center for Devices and Radiological Health (HFZ-440), Food and Drug Administration, 2098

Gaither Rd., Rockville, MD 20850, 301-594-1243.

SUPPLEMENTARY INFORMATION: In the **Federal Register** of August 13, 1998 (63 FR 43401), FDA announced that a joint meeting of the Hematology and Pathology Devices Panel and the Immunology Devices Panel of the Medical Devices Advisory Committee would be held on September 4, 1998.

On page 43401, in the second column, the "*Date and Time*" portion is amended to read as follows:

Date and Time: The meeting will be held on September 4, 1998, 8 a.m. to 3:30 p.m.

On page 43401, in the third column, the "*Procedure*" portion is amended to read as follows:

Procedure: Interested persons may present data, information, or views, orally or in writing, on issues pending before the committee. Written submissions may be made to the contact person by August 21, 1998. Oral presentations from the public will be scheduled between approximately 8:15 a.m. and 8:45 a.m. * * *.

Dated: August 24, 1998.

Michael A. Friedman,

Deputy Commissioner for Operations.

[FR Doc. 98-23265 Filed 8-26-98; 8:45 am]

BILLING CODE 4160-01-F

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

[Docket No. 97N-0424]

Agency Information Collection Activities; Announcement of OMB Approval; Transmittal of Advertisements and Promotional Labeling for Drugs and Biologics for Human Use

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice.

SUMMARY: The Food and Drug Administration (FDA) is announcing that a collection of information entitled "Transmittal of Advertisements and Promotional Labeling for Drugs and Biologics for Human Use" has been approved by the Office of Management and Budget (OMB) under the Paperwork Reduction Act of 1995 (the PRA).

FOR FURTHER INFORMATION CONTACT:

Karen L. Nelson, Office of Information Resources Management (HFA-250), Food and Drug Administration, 5600 Fishers Lane, Rockville, MD 20857, 301-827-1482.

SUPPLEMENTARY INFORMATION: In the **Federal Register** of Friday, October 24, 1997 (62 FR 55408), the agency announced that the proposed information collection had been submitted to OMB for review and clearance under section 3507 of the PRA (44 U.S.C. 3507). An agency may not conduct or sponsor, and a person is not required to respond to, a collection of information unless it displays a currently valid OMB control number. OMB has now approved the information collection and has assigned OMB control number 0910-0376. The approval expires on August 31, 2001.

Dated: August 22, 1998.

William K. Hubbard,

Associate Commissioner for Policy Coordination.

[FR Doc. 98-23105 Filed 8-27-98; 8:45 am]

BILLING CODE 4160-01-F

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

National Cancer Institute; Notice of Meeting

Pursuant to section 10(a) of the Federal Advisory Committee Act, as amended (5 U.S.C. Appendix 2), notice is hereby given of a meeting of the President's Cancer Panel.

The meeting will be open to the public, with attendance limited to space available. Individuals who plan to attend and need special assistance, such as sign language interpretation or other reasonable accommodations, should notify the Contact Person listed below in advance of the meeting:

Name of Committee: President's Cancer Panel.

Date: October 6, 1998.

Time: 8:30 AM to 5:30 PM.

Agenda: Quality of Cancer Care/Quality of Life Decision Making Based on Quality of Care Guidelines and Their Impact.

Place: Roswell Park Cancer Institute, Hilleboe Auditorium, Research Studies Center, Elm and Carlton Street, Buffalo, NY 14263.

Contact Person: Maureen O. Wilson, Executive Secretary, National Cancer Institute, National Institutes of Health, 31 Center Drive, Building 31, Room 4A48, Bethesda, MD 20892.

(Catalogue of Federal Domestic Assistance Program Nos. 93.392, Cancer Construction; 93.393, Cancer Cause and Prevention Research; 93.394, Cancer Detection and Diagnosis Research; 93.395, Cancer Treatment Research; 93.396, Cancer Biology Research; 93.397, Cancer Centers Support; 93.398, Cancer Research Manpower; 93.399, Cancer Control, National Institutes of Health, HHS)

Dated: August 20, 1998.

LaVerne Y. Stringfield,

Committee Management Officer, NIH.

[FR Doc. 98-23187 Filed 8-27-98; 8:45 am]

BILLING CODE 4140-01-M

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

National Cancer Institute; Notice of Meetings

Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. Appendix 2), notice is hereby given of meetings of the National Cancer Advisory Board.

The meetings will be open to the public as indicated below, with attendance limited to space available. Individuals who plan to attend and need special assistance, such as sign language interpretation or other reasonable accommodations, should notify the Contact Person listed below in advance of the meeting.

The meetings will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and/or contract proposals and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications and/or contract proposals, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

Name of Committee: National Cancer Advisory Board, Subcommittee on Planning and Budget.

Date: September 9, 1998.

Time: 7:00 PM to 9:00 PM.

Agenda: To discuss NCI budget and various planning issues.

Place: The Hyatt Regency Hotel, 100 Bethesda Metro Center, Bethesda, MD 20814.

Contact Person: Marvin R. Kalt, Executive Secretary, Division of Extramural Activities, National Cancer Institute, National Institutes of Health, Executive Plaza North—Suite 600, 6130 Executive Boulevard, Rockville, MD 20892, (301) 496-5147.

Name of Committee: National Cancer Advisory Board.

Date: September 9-11, 1998.

Open: September 10, 1998, 9:00 AM to 4:00 PM.

Agenda: Reports from: NCI Director, President's Cancer Panel, NCI Prostate Cancer Program, NCI Breast Cancer Program, Chernobyl Update, and Legislative Update.

Place: Building 31C, Conference Room 10, National Institutes of Health, 3100 Center Drive, Bethesda, MD 20892.

Closed: September 10, 1998, 4:15 PM to Adjournment.

Agenda: To review and evaluate grant applications and/or proposals.

Place: Building 31C, Conference Room 10, National Institutes of Health, 3100 Center Drive, Bethesda, MD 20892.

Open: September 11, 1998, 9:00 AM to 12:10 PM.

Agenda: Cancer Information Service Response to the Office of the Inspector General Report; Subcommittee Reports and New Business; Informed consent revision initiative; Streamlined review of Amended Program Project Review Grants; and future agenda items.

Place: Building 31C, Conference Room 10, National Institutes of Health, 3100 Center Drive, Bethesda, MD 20892.

Contact Person: Marvin R. Kalt, Executive Secretary, Division of Extramural Activities, National Cancer Institute, National Institutes of Health, Executive Plaza North—Suite 600, 6130 Executive Boulevard, Rockville, MD 20892, (301) 496-5147.

Name of Committee: National Cancer Advisory Board, Subcommittee on Cancer Centers.

Date: September 10, 1998.

Time: 12:50 PM to 2:35 PM.

Agenda: To discuss policy and procedure of Cancer Center Programs.

Place: Building 31C, Conference Room 10, National Institutes of Health, 3100 Center Drive, Bethesda, MD 20892.

Contact Person: Marvin R. Kalt, Executive Secretary, Division of Extramural Activities, National Cancer Institute, National Institutes of Health, Executive Plaza North—Suite 600, 6130 Executive Boulevard, Rockville, MD 20892, (301) 496-5147.

(Catalogue of Federal Domestic Assistance Program Nos. 93.393, Cancer Cause and Prevention Research; 93.394, Cancer Detection and Diagnosis Research; 93.395, Cancer Treatment Research; 93.396, Cancer Biology Research; 93.397, Cancer Centers Support; 93.398, Cancer Research Manpower; 93.399, Cancer Control; 93.392, Cancer Construction, National Institutes of Health, HHS)

Dated: August 21, 1998.

LaVerne Y. Stringfield,

Committee Management Officer, NIH.

[FR Doc. 98-23189 Filed 8-27-98; 8:45 am]

BILLING CODE 4140-01-M

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

National Cancer Institutes, Notice of Meetings

Pursuant to section 10(a) of the Federal Advisory Committee Act, as amended (5 U.S.C. Appendix 2), notice is hereby given of meetings of the National Cancer Institute Board of Scientific Advisors.

The meetings will be open to the public, with attendance limited to space

available. Individuals who plan to attend and need special assistance, such as sign language interpretation or other reasonable accommodations, should notify the Contact Person listed below in advance of the meeting.

Name of Committee: National Cancer Institute Board of Scientific Advisors, Subcommittee A—Cancer Biology, Epidemiology, Genetics.

Date: September 22-23, 1998.

Time: 6:30 PM to 6:00 PM.

Agenda: Tobacco, Clinical Trials, and Developmental Therapeutics Program Review Implementations Reports.

Place: Omni Shoreham, 25000 Calvert Street, N.W., Washington, DC 20008.

Contact Person: Paulette S. Gray, Executive Secretary, Division of Extramural Activities, National Cancer Institute, National Institutes of Health, 6130 Executive Boulevard—Room 600C, Rockville, MD 20892-7405, 301/496-4218.

Name of Committee: National Cancer Institute Board of Scientific Advisors, Subcommittee B—Prevention, Clinical, and Therapeutics.

Date: September 22-23, 1998.

Time: 6:30 PM to 6:00 PM.

Agenda: Tobacco, Clinical Trials, and Developmental Therapeutics Program Review Implementations Reports.

Place: Omni Shoreham, 25000 Calvert Street, N.W., Washington, DC 20008.

Contact Person: Paulette S. Gray, Executive Secretary, Division of Extramural Activities, National Cancer Institute, National Institutes of Health, 6130 Executive Boulevard—Room 600C, Rockville, MD 20892-7405, 301/496-4218.

(Catalogue of Federal Domestic Assistance Program Nos. 93.392, Cancer Construction; 93.393, Cancer Cause and Prevention Research; 93.394, Cancer Detection and Diagnosis Research; 93.395, Cancer Treatment Research; 93.396, Cancer Biology Research; 93.397, Cancer Centers Support; 93.398, Cancer Research Manpower; 93.399, Cancer Control, National Institutes of Health, HHS)

Dated: August 24, 1998.

LaVerne Y. Stringfield,

Committee Management Officer, NIH.

[FR Doc. 98-23196 Filed 8-27-98; 8:45 am]

BILLING CODE 4140-01-M

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

National Eye Institute; Notice of Meeting

Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. Appendix 2), notice is hereby given of a meeting of the National Advisory Eye Council.

The meeting will be open to the public as indicated below, with attendance limited to space available.